First Manhattan CO. LLC. Has $333,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

First Manhattan CO. LLC. lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 64.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,675 shares of the company’s stock after selling 40,000 shares during the quarter. First Manhattan CO. LLC.’s holdings in Teva Pharmaceutical Industries were worth $333,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Jump Financial LLC grew its position in Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after buying an additional 838,423 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after buying an additional 134,705 shares in the last quarter. Financial Sense Advisors Inc. grew its position in Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock worth $6,231,000 after buying an additional 157,421 shares in the last quarter. King Wealth Management Group grew its position in Teva Pharmaceutical Industries by 1,106.9% during the first quarter. King Wealth Management Group now owns 175,000 shares of the company’s stock worth $2,690,000 after buying an additional 160,500 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Teva Pharmaceutical Industries by 804.7% during the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock worth $1,037,000 after buying an additional 60,016 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $24.71.

Teva Pharmaceutical Industries Trading Up 0.1%

NYSE TEVA opened at $18.77 on Thursday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a market cap of $21.52 billion, a price-to-earnings ratio of -117.28, a price-to-earnings-growth ratio of 1.09 and a beta of 0.72. The business’s fifty day moving average is $16.95 and its 200 day moving average is $16.37.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the business posted $0.61 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.